Streetbeat News

Earnings

HTBK

Heritage Commerce Corp reported Q4 earnings of $0.22 per share, missing the consensus estimate of $0.24, and sales of $44.24M, also below the expected $44.54M. This reflects a significant decrease from the previous year's earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:56 am

HMNF

HMN Financial Inc. (HMNF) reported a decrease in earnings and sales for Q4, with EPS dropping to $0.33 from $0.56 YoY and sales falling to $9.36M from $10.86M YoY.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:52 am

RMBI

Richmond Mutual Bancorp (NASDAQ:RMBI) reported a decrease in Q4 earnings to $0.19 per share, down from $0.31 YoY. Sales also fell to $10.51M from $11.91M YoY, marking a 11.79% decline.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:49 am

FRST

Primis Financial Corp. (FRST) reported Q4 adjusted EPS of $0.35, surpassing the $0.28 estimate, marking a 191.67% increase from last year's $0.12. Sales reached $39.24M, exceeding the $27.05M estimate but showing a 3.27% decrease from the previous year's $40.56M.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:48 am

VLVCY

VLVLY

Volvo reported a strong Q4 2023 with a 10% increase in net sales to SEK 148.1 billion and a significant rise in EPS to SEK 5.93 from SEK 3.26 YoY. Adjusted operating income was SEK 18,384 M, up from SEK 12,171 M, with a margin of 12.4%. Currency movements positively impacted operating income by SEK 1,106 M, and operating cash flow in the Industrial Operations was SEK 22,655 M.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:37 am

RHHBY

Roche's Genentech has announced new long-term data for Vabysmo, showing sustained improvements in retinal drying and vision for patients with Retinal Vein Occlusion (RVO). The data indicates that up to 60% of patients could extend treatment intervals to three or four months. Detailed results from two global Phase III RVO studies will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 6:33 am

TSLA

Tesla Inc's Chief Designer Franz von Holzhausen had an exchange with the Cybertruck account on X, featuring a black-wrapped Cybertruck photo from Tesla's Q4 earnings report. The Cybertruck's design is considered futuristic, and Tesla's Supply Chain VP Karn Budhiraj noted strong conversion of reservations to orders, with potential to sell out all builds in 2024. Elon Musk aims to deliver 250,000 Cybertrucks in North America.

Portfolio Pulse from Anan Ashraf

January 26, 2024 | 4:40 am

TSLA

Elon Musk clarified his previous comments about the Dojo supercomputer's success odds, comparing them to the initial low success expectations he had for Tesla and SpaceX. During Tesla's Q4 earnings call, Musk described Dojo as a 'long shot' with high risk and high potential payoff, noting that Tesla is scaling the project and planning future versions.

Portfolio Pulse from Anan Ashraf

January 26, 2024 | 3:29 am

ARKK

ARKW

TSLA

Tesla, Inc. (TSLA) shares dropped over 12% after Q4 earnings missed expectations, leading to a market cap loss of $80.4 billion. Despite this, Ark Invest, led by Cathie Wood, purchased $32.5 million worth of Tesla shares through ARKK and ARKW ETFs. Ark remains bullish on Tesla, with a $2000 price target by 2027, largely based on the potential of Tesla's robotaxi service. The short-term outlook for Tesla stock is uncertain, with potential influences including economic data releases and the Fed's rate decision.

Portfolio Pulse from Shanthi Rexaline

January 26, 2024 | 3:06 am

AMD

INTC

NVDA

PCSA

TSLA

U.S. stocks closed higher with Intel, Nvidia, AMD, Processa Pharmaceuticals, and Tesla being the focus of investors. Intel rose 0.94% after reporting a 10% year-over-year revenue increase. Nvidia fell 0.42% but remains a key player in AI. AMD gained 1.14% with raised estimates from UBS. Processa Pharmaceuticals surged 148.78% on successful drug trial results. Tesla dropped 12.13% after missing Q4 revenue and EPS estimates, with analysts expressing concern over its valuation.

Portfolio Pulse from Benzinga Neuro

January 26, 2024 | 2:14 am